NOROMBY HP SOLUTION

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

ENOXAPARIN SODIUM

から入手可能:

JUNO PHARMACEUTICALS CORP.

ATCコード:

B01AB05

INN（国際名）:

ENOXAPARIN

投薬量:

150MG

医薬品形態:

SOLUTION

構図:

ENOXAPARIN SODIUM 150MG

投与経路:

INTRAVENOUS

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

治療領域:

HEPARINS

製品概要:

Active ingredient group (AIG) number: 0131860002; AHFS:

認証ステータス:

APPROVED

承認日:

2020-10-14

製品の特徴

_ _
_NOROMBY _
_Page 1 of 78_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
NOROMBY
TM
Enoxaparin sodium
Solution for injection, 100 mg/mL
BP
20 mg/0.2 mL
30 mg/0.3 mL
40 mg/0.4 mL
60 mg/0.6 mL
80 mg/0.8 mL
100 mg/mL
(Subcutaneous or Intravenous Use Only)
Pr
NOROMBY
TM HP
Enoxaparin sodium
Solution for injection, 150 mg/mL
BP
120 mg/0.8 mL
150 mg/mL
(Subcutaneous or Intravenous Use Only)
ATC Code: B01AB05
Anticoagulant/Antithrombotic Agent
Juno Pharmaceuticals Corp.
402-2233 Argentia Road
Mississauga, Ontario
L5N 2X7
Date of Initial Approval:
October 14, 2020
Date of Revision:
February 12, 2021
Submission Control No: 233058
_ _
_NOROMBY _
_Page 2 of 78_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...............................................................4
1
INDICATIONS
..............................................................................................................4
1.1
Pediatrics
............................................................................................................4
1.2
Geriatrics
............................................................................................................4
2
CONTRAINDICATIONS................................................................................................4
3
DOSAGE AND
ADMINISTRATION...............................................................................5
3.1
Dosing
Considerations.........................................................................................5
3.2
Recommended Dose and Dosage Adjustment
.....................................................5
3.3
Administration
.....................................................................................................8
3.4
Missed Dose
.....................................................................................................10
4
OVERDOSAGE
..........................................................................................................10
5
DOSAGE FORMS, STRENGTHS, COMPOSITION AND
PACKAGING................